<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Poveda, Andrés</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">AURELIA Analysis Shows Benefits of Bevacizumab as Add-on Therapy in Ovarian Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">In patients with ovarian cancer, progression-free survival and overall response rate are significantly improved with the addition of bevacizumab to chemotherapy in front-line [Burger RA et al. N Engl J Med 2011] and platinum-sensitive recurrent [Aghajanian C et al. J Clin Oncol 2012] settings, and as shown in the Phase 3 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer [AURELIA; NCT00976911] trial [Pujade-Lauraine E et al. J Clin Oncol 2012].</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>